Colchicine Increases Ventricular Vulnerability in an Experimental Whole-Heart Model

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Colchicine is a traditional gout medication.
• Clinical trials suggest colchicine may prevent atrial fibrillation recurrence after ablation or surgery.
• Severe adverse events have not been reported in prior studies.

Purpose of the Study:

• To assess the direct electrophysiological effects of colchicine.
• To investigate colchicine's potential pro-arrhythmic effects in an experimental model.

Main Methods:

• Isolated Langendorff-perfused rabbit hearts (n=10).
• Administration of colchicine at 1 μM and 3 μM concentrations.
• Measurement of monophasic action potentials and 12-lead ECG.

Main Results:

• Colchicine did not alter QT interval or action potential duration.
• No significant increase in repolarization dispersion was observed.
• Colchicine significantly decreased the effective refractory period (ERP) in a dose-dependent manner.
• Ventricular fibrillation inducibility was significantly elevated, with incessant ventricular fibrillation in 40% of hearts.

Conclusions:

• Colchicine demonstrated a dose-dependent reduction in ERP and increased ventricular fibrillation inducibility in an experimental model.
• These findings suggest a potential pro-arrhythmic or toxic effect of colchicine.
• Further clinical investigation into colchicine's adverse effects is warranted before its routine use in preventing atrial fibrillation recurrence.